Ocugen Inc

NASDAQ:OCGN   3:59:53 PM EDT
2.88
+0.04 (+1.41%)
Earnings Announcements

Ocugen Inc Says Expanding Product Pipeline With Regenerative Medicine Cell Therapy Program Neocart

Published: 08/05/2022 11:50 GMT
Ocugen Inc (OCGN) - Ocugen Provides Business Update & Second Quarter 2022 Financial Results.
Cash, Cash Equivalents, and Restricted Cash Totaled $115.0 Million As of June 30, 2022, Compared to $95.1 Million As of December 31, 2021.
Believes That Its Current Cash and Cash Equivalents Balance Will Enable It to Fund Its Operations Into Q2 of 2023.
Reported a $0.09 Net Loss per Share for Three Months Ended June 30, 2022.
Dosing Patients in U.S. Phase 2/3 Covaxin™ (bbv152) Clinical Trial.
Expanding Product Pipeline With Regenerative Medicine Cell Therapy Program Neocart.
Q2 Earnings per Share View $-0.08 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.09

Next Quarter Revenue Guidance is expected to be $0.22 Million
Next Quarter EPS Guidance is expected to be -$0.09

More details on our Analysts Page.